BERWYN, PA — Nordic Pharma, Inc., a subsidiary of Nordic Group B.V., recently introduced LACRIFILL Canalicular Gel, a new therapy for dry eye, to the U.S. market. This innovative treatment utilizes a cross-linked hyaluronic acid derivative and has received FDA clearance for temporarily blocking tear drainage by occluding the canalicular system.
LACRIFILL Canalicular Gel allows patients’ eyes to benefit from their own natural tears by providing a customized full fill of the canalicular system. The gel is administered through a simple in-office procedure that is reimbursed through an existing CPT code, with results lasting up to six months.
“It’s been exciting to be part of the launch of LACRIFILL Canalicular Gel,” said Jai Parekh, MD, MBA, Chief Commercial Officer of Eye Care U.S. “This interventional dry eye treatment assists ophthalmologists with cataract, glaucoma, and refractive surgeries and addresses all dry eye needs. This therapy is truly changing practice and changing lives.”
Nordic Pharma presented information about LACRIFILL Canalicular Gel at Kiawah Eye 2024 in Kiawah Island, SC, which took place from May 30 to June 1. “LACRIFILL Canalicular Gel is a disruptive technology that will change how ophthalmologists practice,” said Eric D. Donnenfeld, MD, Program Director for Kiawah Eye and chairperson of the LACRIFILL U.S. Medical Advisory Board. “Having Nordic Pharma onsite to discuss how LACRIFILL Canalicular Gel can optimally occlude the canalicular system to maximize tear film preservation will be incredibly beneficial for attendees.”
The launch of LACRIFILL Canalicular Gel marks a significant advancement in the treatment of dry eye, offering patients a new option for managing their condition while helping ophthalmologists improve patient outcomes.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.